Targeting the Gut-Brain Axis in Functional Dyspepsia: Buspirone and Mirtazapine Improve Anxiety and PAGI-SYM Scores
In brief
In 71 patients, buspirone and mirtazapine beat pantoprazole over 12 weeks
In this 71-patient study, buspirone and mirtazapine both reduced anxiety and functional dyspepsia symptoms more than pantoprazole alone after 12 weeks, with no clear difference between the two drugs. The results suggest these medicines could address both concerns, but the small study does not establish how large or lasting the benefits are.
- Journal
- Neurogastroenterology and motility (Q1)
- Published
- 1 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Mahdieh Khorashadizadeh, Fatemeh Salmani, Tahmine Tavakoli
- PMID
- 43004923
- DOI
- 10.1111/nmo.70479
Why clinicians should know about it
- Picked for Gastroenterology (top studies of the week, 15 November 2026): Medication comparison for functional dyspepsia symptoms
Abstract
BACKGROUND: Functional dyspepsia is a chronic gastrointestinal disorder with uncertain causes, often linked to anxiety and depression, which can worsen symptoms and hinder treatment success. Although psychological therapies and antidepressants have shown some benefit, the role of anti-anxiety medications remains unclear. This study aims to evaluate the effectiveness of buspirone and mirtazapine in reducing symptoms and improving the quality of life for patients with functional dyspepsia. METHODS: In a semi experimental study, 71 patients with functional dyspepsia were randomized to receive either buspirone 15 mg, mirtazapine 7.5 mg, or pantoprazole 40 mg once daily for 12 weeks. Outcomes-anxiety severity, dyspepsia symptom score, quality of life, and adverse events-were assessed at baseline and monthly. Efficacy was analyzed by repeated-measures ANOVA and adverse event rates by chi-square tests. RESULTS: Both buspirone and mirtazapine significantly outperformed pantoprazole alone in reducing anxiety (buspirone vs. control at 3 months, p = 0.01; both active treatments vs. control, p < 0.05) and in alleviating functional dyspepsia symptoms by Week 12 (both vs. control, p < 0.05), with no difference between the two active drugs. CONCLUSIONS: This study suggests that buspirone and mirtazapine are effective in reducing anxiety and improving symptoms in patients with functional dyspepsia. These findings highlight the potential role of anti-anxiety medications in managing both the psychological and gastrointestinal aspects of this disorder.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.